The therapeutic-indication claim documented directly in the FDA’s 1954 complaint, which quotes the accumulator’s own accompanying labeling (including the booklet The Orgone Energy Accumulator — Its Scientific and Medical Use, c. 1951) as representing that “the devices were outstanding therapeutic agents; that they were preventive of, and beneficial for use in, all diseases and disease conditions,” and lists dozens of named conditions verbatim, among them “cancer,” “tumor of breasts,” “elimination of cancer tumors,” “lung cancer,” “inoperable cancer of esophagus,” “prevention of metastasis,” “leukemia,” “diabetes,” “epilepsy,” “multiple sclerosis,” “angina pectoris,” and “myocardial infarction,” as well as general protective claims (“counteracts nuclear radiation,” “pneumonia preventive,” and use “for shock, epidemics, blood, and tissues”). No controlled trial of the accumulator against any of these conditions was published. Classified as testimonial because the labeling’s supporting evidence was case reports and patient/practitioner testimonial, not controlled outcome data; classified refuted because the accumulator’s core mechanism claim was itself found nonexistent (see the mechanism claim above), and the labeling was found false and misleading under the Federal Food, Drug, and Cosmetic Act by the 1954 default injunction.